Chronic Lymphocytic Leukemia
• The role of BTK monotherapy
• Bcl-2 inhibitor combinations
• Biology and clonal evolution of CLL
• Cellular therapies for CLL
• Monoclonals and bispecifics in CLL
• Novel approaches to Richter’s
transformation
Huang et al., Front Cell Dev Biol. 2021
Ocana et al., Oncotarget. 2017
Multiple Myeloma
• Smoldering myeloma and special populations
• T-cell engagers in MM
• CAR-T for MM
• Predictive biomarkers and precision therapy
Brentjens and Curran. Hematology Am Soc Hematol Educ Program. 2017
Van de Donk et al., Lancet Oncol. 2021
Lymphoma
• Chemo-free therapy for DLBCL
• Peripheral T-cell lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Waldenström macroglobulinemia
• Follicular lymphoma
• Hodgkin Lymphoma
• Uncommon lymphoma subtypes
• Bispecifics as monotherapy in B-cell
lymphoma
• Combination therapy for B-cell lymphoma
Mihalyova et al., Int J Mol Sci. 2021
Leukemia and MDS/MPN
• Acute myeloid leukemia
• Acute lymphoblastic leukemia
• Translational biology of AML, MDS,
and MPN
• Molecularly targeted therapies for AML,
ALL, and MPN
• Myelofibrosis
• Mastocytosis
• Hairy cell leukemia
• Chronic neutrophilic leukemia
• Large granular lymphocyte leukemia
Gurney and O’Dwyer, Cancers. 2021
Figure 1. Myeloproliferative neoplasms and myelodysplastic syndromes.
Figure 2. A schematic description of genotypic diversity in patients with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
Mullighan, Nat Genet. 2009
DAVA Oncology
2700 W Plano PKWY, Plano, TX 75075 PH: 214-451-4500